
Figure. Distribution of pathogens most frequently associated with community onset urinary tract infections



Conclusion: Understanding patient factors associated with the microbiology of coUTIs is an important step in developing treatment recommendations and antibiotic stewardship efforts. Further analyses will include assessing the impact of major antibiotic resistance phenotypes, geographic and healthcare settings. Disclosures. All Authors: No reported disclosures

1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study

I. Scott Overcash, MD, FACEP¹; Evan Tzanis, BS²; Amy Manley, BS²; Courtney Kirsch, BS2; Alisa W. Serio, PhD2; Tiffany White, PhD2; Kelly Wright, PharmD²; Surya Chitra, PhD²; Paul B. Eckburg, MD³; ¹eStudySite, San Diego, CA. San Diego, CA; ²Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania; ³Selfemployed, Mountain View, CA

Session: P-73. UTIs

Background. Omadacycline (OMC) is a novel intravenous (IV) and oral aminomethylcycline, approved in the USA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults. We present data from a randomized, adaptive dose-response phase 2 study of OMC in adult females with acute pyelonephritis (AP).

Methods. Females aged \geq 18 y with acute uncomplicated pyelonephritis were initially randomized to 1 of 4 once-daily regimens of OMC vs once-daily standard regimen of IV-to-oral levofloxacin (LEV) (total therapy: 7-10 days) (NCT03757234); the randomization algorithm was subsequently adapted by the data monitoring committee (DMC; blinded to the investigators) following interim analyses of efficacy in the microbiological-intent-to-treat (micro-ITT) population (Table 1). Efficacy was assessed for noninferiority according to investigator's assessment of clinical response (IACR) and microbiological response at post-therapy evaluation (PTE; Day 21) and end of therapy (EOT). Treatment-emergent adverse events (TEAEs) were assessed. Results were reviewed by the DMC.

Table 1

Table 1. Study Design and Dosing Groups^a

Group	Test Article	Study Day 1	Study Days 2–10	Interim Analysis
1	Omadacycline	200 mg IV	200 mg IV	
2	Omadacycline	200 mg IV	100 mg IV	STOPPED
3	Omadacycline	200 mg IV	300 mg PO or 100 mg IV	STOPPED
4	Omadacycline	200 mg IV	450 mg PO or 100 mg IV	STOPPED
5	Levofloxacin	750 mg IV	750 mg PO or IV	

IV, intravenous; LEV, levofloxacin; OMC, omadacycline, PO, oral

*Initially, participants were randomized to 1 of 5 treatment groups. Interim analyses were conducted by the data monitoring committee (blinded to investigators) in the microbiological-intent-to-treat (micro-ITT) population (all randomized participants who had ≥1 uropathogen in baseline urine culture present at ≥10 colony-forming units/mL, and ≤2 bacterial isolates at any colony count), at which point randomization into 3 of the 4 OMC treatment arms was stopped because of lower response rates.

Results. 201 patients were randomized. Baseline characteristics were similar across groups (Table 2). Among patients with an identified pathogen, the most common species was E. coli. For IACR at both EOT and PTE, no OMC group met noninferiority to LEV (Figure 1), as the lower limit of the 95% CI for the treatment difference exceeded -10% (range -12.4% to -34.8%). Responses at PTE were consistent with those at EOT. Microbiological responses in each OMC group were generally lower than LEV. OMC was well tolerated; 36.2% and 32.4% of OMC- and LEV-treated patients had \geq 1 TEAE. The most frequently reported TEAEs (\geq 5%) in the OMC the LEV groups, respectively, were headache (10.2% vs 6.8%), asymptomatic bacteriuria (6.3% vs 1.4%), diarrhea (2.4% vs 6.8%), and nausea (5.5% vs 6.8%).

Table 2

Table 2. Demographic and Baseline Characteristics. ITT Population^a

	Omadacycline				
	300 mg PO or 450 mg PO or		450 mg PO or		
	200 mg IV	100 mg IV	100 mg IV	100 mg IV	LEV
	n=75	n=18	n=17	n=17	n=74
Age, years, mean (SD)	38.2 (15.0)	33.9 (14.5)	37.1 (16.0)	38.2 (17.7)	38.8 (14.7)
Race, % (n)					
White	98.7 (74)	100 (18)	100 (17)	100 (17)	100 (74)
Other	1.3 (1)	-	-	-	-
Veight, kg; mean (SD)	68.1 (15.2)	65.5 (15.5)	68.5 (14.9)	69.5 (21.2)	66.4 (13.7)
Body mass index, kg/m ² , mean (SD)	25.3 (5.7)	23.8 (6.2)	24.4 (6.0)	25.2 (7.1)	24.4 (6.0)
Renal function, n (%)					
Normal renal function [>89 mL/min]	59 (78.7)	16 (88.9)	13 (76.5)	13 (76.5)	48 (64.9
Mild renal impairment [>60-89 mL/min]	12 (16.0)	1 (5.6)	3 (17.6)	4 (23.5)	20 (27.0)
Moderate renal impairment [30-60 mL/min]	4 (5.3)	1 (5.6)	1 (5.9)	0	6 (8.1)
Baseline pathogens, n (%)					
micro-ITT population) ^d					
Escherichia coli	36 (78.3)	11 (100)	12 (85.7)	9 (69.2)	45 (86.5)
Klebsiella pneumoniae	6 (13.0)	0	0	0	3 (5.8)
Proteus mirabilis	1 (2.2)	0	1 (7.1)	1 (7.7)	1 (1.9)
Pseudomonas aeruginosa	0	0	0	1 (7.7)	2 (3.8)
Enterococcus faecalis	3 (6.5)	0	0	0	1 (1.9)

AP, acute pyelonephritis; ITT, intent UTI, urinary tract infection. nous; LEV, levofloxacin; OMC, omadacycline; PO, oral; QD, once daily; SD, standard deviat

JH, Umany Yurks messawa. ITT population was all randomized participants. Odd Creatment arms are described by dosing regimen for Days 2–10. All OMC treatment arms used 200 mg IV dosing on Day 1. Odd Creatment arms are described by dosing regimen for Days 2–10. All OMC treatment arms used 200 mg IV dosing on Day 1. Control of the standard based on creatinine clearance at baseline, calculated from the Cockordfr-Gault equation for females are standard based on creatinine clearance at baseline. Micro-ITT: All rands zed subjects who had a study-qualifying pre-treatment baseline urine culture.

Figure

Figure 1. Forest Plot of Efficacy Endpoints

	Omadacycline*	Levofloxacin		Difference [95% CI]	Non- inferiority vs Levofloxacin ^b
Clinical Success at PTE, ITT Pop	ulation ^c , % (n)				
200 mg IV	90.7 (68/75)		····• .	-2.6 [-12.4, 6.9]	0.95
100 mg IV	83.3 (15/18)	93.2 (68/74)		-9.9 [-34.8, 5.3]	0.49
300 mg PO or 100 mg IV	88.2 (15/17)	93.2 (08/74)		-5.0 [-30.6, 8.2]	0.70
450 mg PO or 100 mg IV	94.1 (16/17)			0.9 [-22.3, 11.8]	0.8955
Per-participant Microbiologica	Response at PTE,				
Micro-ITT Population	n ^d , % (n)				
200 mg IV	69.6 (32/46)			-5.4 [-23.6, 12.7]	-
100 mg IV	27.3 (3/11)	75.0 (39/52)		-47.7 [-71.3, -6.0]	-
300 mg PO or 100 mg IV	64.3 (9/14)	75.0 (39/52)		-10.7 [-40.8, 15.1]	-
450 mg PO or 100 mg IV	38.5 (5/13)		· · · · · ·	-36.5 [-62.6, -1.1]	-

P value for

Cl, confidence interval; ITT, intent-to-treat; IV, intravenous; EV, levofloxacir; OMC, omadescripter PO, on FTP, post-therapy evaluation; OD, once dail ^a OMC treatment arms are described by dooing regimen for Days 2–10. All OMC treatment arms used 200 mg V dooing on Day 1. ^b Nonriferiority margin was 10%. If the lower limit of the 95% CI for the difference exceeded – 10%, then the null hypothesis was rejected and the noninteriority of OHC to LV was detected for that does. The posterior probability of noninteriority of the OMC treatment arms will was acadulated. ^c ITT population; All randomized participants. ^c MincorfT population; All randomized participants. ny evaluation: OD, once dails

Conclusion: In this adaptive, phase 2 study, clinical success was high for both groups, although no OMC group met criteria for noninferiority to levofloxacin in AP, potentially due to pharmacokinetic/pharmacodynamic drivers of efficacy for AP. Omadacycline was well tolerated, with a safety profile consistent with its current labeling. Further evaluation is warranted to further understand the outcomes of this study.

Disclosures. J. Scott Overcash, MD, FACEP, Paratek Pharmaceuticals, Inc. (Scientific Research Study Investigator) Evan Tzanis, BS, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Amy Manley, BS, Paratek Pharmaceuticals, Inc. (Employee) Courtney Kirsch, BS, Paratek Pharmaceuticals, Inc. (Employee) Alisa W. Serio, PhD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Tiffany White, PhD, ContraFact Corporation (Consultant, (ended Feb 2020)) Facile Therapeutics (Consultant)Paratek Pharmaceuticals, Inc. (Employee) Kelly Wright, PharmD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Surya Chitra, PhD, Paratek Pharmaceuticals, Inc. (Consultant) Paul B. Eckburg, MD, AN2 Therapeutics (Consultant)Bugworks Research (Consultant)Curza (Advisor or Review Panel member)Paratek Pharmaceuticals, Inc. (Consultant)SNIPR Biome (Consultant)Spero Therapeutics (Consultant)

1688. Omadacycline in Female Adults With Cystitis: Results From a Randomized, Double-Blinded, Adaptive Phase 2 Study

J. Scott Overcash, MD, FACEP¹; Evan Tzanis, BS²; Amy Manley, BS²; Alissa Sirbu, BSN²; Alisa W. Serio, PhD²; Tiffany White, PhD²; Kelly Wright, PharmD²; Surya Chitra, PhD²; Paul B. Eckburg, MD³; ¹eStudySite, San Diego, CA, San Diego, CA; ²Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania; ³Self-employed, Mountain View, CA

Session: P-73. UTIs

Background. In a previous phase 1b study, \geq 90% of patients with cystitis treated with omadacycline (OMC), a novel intravenous (IV) and oral aminomethylcycline, achieved clinical success. We assessed the safety and efficacy of OMC vs nitrofurantoin (NIT) for treatment of cystitis in a randomized, adaptive phase 2 study.

Methods. Females ≥18 years with uncomplicated symptomatic cystitis were randomized to oral dose regimens of OMC or NIT for 7 days (NCT03425396; Table 1). Efficacy was assessed for noninferiority by investigator's assessment of clinical response (IACR) at post-treatment evaluation (PTE; primary endpoint; Day 14). Other endpoints included IACR, microbiologic response, and composite clinical and microbiologic response at end of treatment (EOT) and PTE. Treatment-emergent adverse events (TEAEs) were assessed. Results were reviewed by a data monitoring committee.

Table 1
Table 1

Group	Test Article	Study Day 1	Study Days 2–7ª	Participants Enrolled, n
1	Omadacycline	300 mg PO q12h, fed	300 mg PO q24h	55
2	Omadacycline	450 mg PO q12h, fed	300 mg PO q24h	54
3	Omadacycline	450 mg PO q12h, fed	450 mg PO q24h	54
4 ^b	Omadacycline	450 mg PO q12h, fed	450 mg PO q12h	8
5	Nitrofurantoin	100 mg PO q12h, fed	100 mg PO q12h	54

fed = patient was not fasted, PO = oral, q12h = once every 12 hours, q24h = once every 24 hours. ^a First doses on Study Days 2–7 were taken in a fasted state. Second doses on Study Days 2–7, where applicable, were administered \sim 2 hours following a light meal.

appression were administered 2 hours following a fight frequencies b^b Group 4 was added per Amendment 2 after the study had already enrolled >80% of planned subjects.

Results. Of 225 patients enrolled, 93.8% completed the study. Baseline (BL) characteristics were similar across groups, except Group 4, which was added late in the study based on blinded review of tolerability. (**Table 2**). Most patients had moderate BL symptoms of urinary tract infection. Among those with an identified pathogen, the most common species was *E. coli*. BL minimum inhibitory concentrations (MICs) against *E. coli* were 0.5 to 8 µg/mL for OMC and < 2 to 64 µg/mL for NIT. Clinical success rates for the intent-to-treat (ITT) population at PTE were high for all groups (OMC 78–88%; NIT 91%; **Figure**). Microbiologic response rates were higher with NIT vs OMC at PTE (**Figure**). Noninferiority of OMC to NIT was not met, as the lower limit of the 95% CI for treatment difference exceeded -10% (range -16.8% to -44.1%). OMC was generally well tolerated, with gastrointestinal disorders as the most frequent TEAEs (OMC 22%; NIT 14.8%).

Table 2

Table 2. Demographic and Baseline Characteristics (Intent-to-Treat Analysis Population)

Characteristic	Omadacycline 300/300 q24h (n=55)	Omadacycline 450/300 q24h (n=54)	Omadacycline 450/450 q24h (n=54)	Omadacycline 450/450 q12h (n=8)	Nitrofurantoir (n=54)
Age, years; mean (SD)	45.3 (17.05)	47.4 (15.70)	45.0 (15.49)	37.5 (13.60)	45.5 (17.82)
Race; n (%)					
White	52 (94.5)	52 (96.3)	48 (88.9)	6 (75.0)	47 (87.0)
Black or African American	2 (3.6)	1 (1.9)	4 (7.4)	2 (25.0)	4 (7.4)
Other	1 (1.8)	1 (1.9)	2 (3.7)	0	3 (5.6)
Weight, kg; mean (SD)	73.5 (12.93)	76.1 (14.92)	76.1 (14.67)	81.5 (16.29)	79.8 (19.42)
Body mass index, kg/m²; mean (SD)	28.4 (4.10)	30.2 (5.85)	29.3 (5.43)	33.7 (12.03)	30.6 (6.66)
Renal function; n (%)*					
Normal renal function [>89 mL/min]	42 (76.4)	43 (79.6)	47 (87.0)	7 (87.5)	44 (81.5)
Mild renal impairment [>60-89 mL/min]	10 (18.2)	8 (14.8)	6 (11.1)	1 (12.5)	9 (16.7)
Moderate renal impairment [30-60 mL/min]	3 (5.5)	3 (5.6)	1 (1.9)	0	1 (1.9)
Urine pH; mean (SD)	6.00 (0.79)	6.01 (0.72)	6.17 (0.99)	5.94 (0.94)	6.08 (0.84)
UTISA symptom severity, n (%)					
Mild	2 (3.6)	2 (3.7)	3 (5.6)	1 (12.5)	4 (7.4)
Moderate	32 (58.2)	30 (55.6)	34 (63.0)	4 (50.0)	35 (64.8)
Severe	20 (36.4)	22 (40.7)	17 (31.5)	3 (37.5)	15 (27.8)
Baseline pathogens, n (%)					
(micro-ITT population ^b)					
Escherichia coli	20/25 (80.0)	30/34 (88.2)	17/23 (73.9)	4/5 (80.0)	23/30 (76.7)
Proteus mirabilis	2/25 (8.0)	1/34 (2.9)	2/23 (8.7)	0	3/30 (10.0)
Klebsiella pneumoniae	1/25 (4.0)	1/34 (2.9)	2/23 (8.7)	0	3/30 (10.0)
Enterococcus faecalis	2/25 (8.0)	1/34 (2.9)	1/23 (4.3)	1/5 (20.0)	2/30 (6.7)
Streptococcus agalactiae	1/25 (4.0)	0	2/23 (8.7)	0	1/30 (3.3)

q12h, every 12 hours; q24h, every 24 hours; 5D, standard deviation; UTISA, Urinary Tract Infection Symptom Assessment. *Renal function is evaluated based on Creatinine Clearance at Baseline, calculated from the Cockcroft-Gault equation for females and non-missing age, weight and creatinini

*Micro-ITT: All randomized subjects who had a study-qualifying pre-treatment baseline urine culture.

Figure

Figure 1. Clinical Success Rates at Post-Treatment Evaluation (PTE) in the Intent-To-Treat (ITT) Population and Microbiological Response Rates at PTE in the Micro-ITT Population

Clinical Success Rates

	Clinical success, % (95% CI)	Difference to nitrofurantoin		P value
ITT			L v	
Omadacycline 300/300 q24h	87.3 (75.5, 84.7)	-3.5 (-16.8, 9.6)		0.866
Omadacycline 450/300 q24h	77.8 (64.4, 88.0)	-13.0 (-27.4, 1.2)	⊢ ▲→1	0.350
Omadacycline 450/450 q24h	85.2 (72.9, 93.4)	-5.6 (-19.6, 7.4)		0.770
Omadacycline 450/450 q12h	87.5 (47.3, 99.7)	-3.2 (-44.1, 14.0)		0.661
Nitrofurantoin	90.7 (79.7, 96.9)	-6	0 -40 -20 0 20 40	

Microbiological Response Rates

Success, % (95% CI) Difference to nitrofurantoin

Micro-III			10.0
Omadacycline 300/300 q24h	56.0 (34.9, 75.6)	-20.7 (-45.1, 6.0)	· • • • • •
Omadacycline 450/300 q24h	58.8 (40.7, 75.4)	-17.8 (-40.2, 5.9)	
Omadacycline 450/450 q24h	65.2 (42.7, 83.6)	-11.4 (-36.8, 14.7)	
Omadacycline 450/450 q12h	80.0 (28.4, 99.5)	3.3 (-47.0, 33.2)	
Nitrofurantoin	76.7 (57.7, 90.1)		-60 -40 -20 0

Composite Response Rates

Micro-ITT	Success, % (95% CI)	Difference to nitrofurantoin	
Omadacycline 300/300 q24h	52.0 (31.3, 72.2)	-21.3 (-46.0, 5.4)	<u>ب</u> ر
Omadacycline 450/300 q24h	50.0 (32.4, 67.6)	-23.3 (-46.1, 1.8)	·
Omadacycline 450/450 q24h	60.9 (38.5, 80.3)	-12.5 (-38.8, 13.7)	
Omadacycline 450/450 q12h	80.0 (28.4, 99.5)	6.7 (-44.8, 36.7)	· · · · · · · · · · · · · · · · · · ·
Nitrofurantoin	73.3 (54.1, 87.7)		-60 -40 -20 0 20 40

Micro-ITT, microbiological intent-to-treat; q12h, every 12 hours; q24h, every 24 hours.

Analysis sets were defined as follows: Intent-to-treat (ITT): all randomized participants; Micro-ITT: all randomized subjects who had a study-qualifying pre-treatment baseline urine culture. Vertical line at -10 indicates the NI margin. **Conclusion:** In this phase 2 study, clinical success rates were high in the OMC and NIT groups, although no OMC group met noninferiority criteria. Microbiological responses with all doses of OMC were generally lower than in the NIT group, potentially influenced by the higher BL MICs observed in this study compared with the previous phase 1b study. OMC was well tolerated, with a safety profile consistent with its current labeling. Further analyses are needed to fully understand study outcomes.

Disclosures. J. Scott Overcash, MD, FACEP, Paratek Pharmaceuticals, Inc. (Scientific Research Study Investigator) Evan Tzanis, BS, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Amy Manley, BS, Paratek Pharmaceuticals, Inc. (Employee) Alissa Sirbu, BSN, Paratek Pharmaceuticals, Inc. (Employee) Alissa Sirbu, BSN, Paratek Pharmaceuticals, Inc. (Employee) Alisa W. Serio, PhD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Tiffany White, PhD, ContraFact Corporation (Consultant, (ended Feb 2020))Facile Therapeutics (Consultant)Paratek Pharmaceuticals, Inc. (Employee) Kelly Wright, PharmD, Paratek Pharmaceuticals, Inc. (Employee, Shareholder) Surya Chitra, PhD, Paratek Pharmaceuticals, Inc. (Consultant)Curza (Advisor or Review Panel member)Paratek Pharmaceuticals, Inc. (Consultant)SNIPR Biome (Consultant)Spero Therapeutics (Consultant)

1689. Oral Beta-lactam Step Down in Bacteremic *E. coli* Urinary Tract Infections

Stephan Saad, MD, FRCPC¹; Neil Mina, MD, FRCPC²; Colin Lee, BSc.Pharm, ACPR, PharmD, MSc.³; Kevin Afra, MD, MHA, FRCPC⁴; ¹University of British Columbia, Coquitlam, British Columbia, Canada; ²Fraser Health, Surrey, British Columbia, Canada; ³Providence Health Care, Vancouver, British Columbia, Canada; ⁴University of British Columbia, Division of Infectious Diseases, Surrey, British Columbia, Canada

Session: P-73. UTIs

Background. Literature is scarce regarding oral step down to beta-lactams in bacteremic urinary tract infections. Oral fluoroquinolones are an accepted and common step down for bacteremic urinary tract infections; however, their use is associated with mounting safety concerns. We compared clinical cure in patients with *E. coli* bacteremic urinary tract infections who were stepped down to oral beta-lactams compared to oral fluoroquinolones.

Methods. This multicentre retrospective cohort study included patients with first positive concurrent urine and blood cultures from January 2016 to December 2016. Patients were included if they received empiric intravenous beta-lactam therapy with step down to either oral beta-lactam or fluoroquinolone for treatment completion. The primary outcome was clinical cure. Secondary outcomes were length of hospitalization, all-cause mortality and *C. difficile* infection. Multivariate analysis and propensity score were used to control for confounding. *Results.* A total of 207 patients were identified with bacteremic *E.coli* urinary

Results. A total of 207 patients were identified with bacteremic *E.coli* urinary tract infections. Clinical cure was achieved in 72/77 (94%) in the oral beta-lactam group versus 127/130 (98%) in the oral fluoroquinolone group (absolute difference -4.2%, 95% confidence interval [CI] -10.3% to 1.9%, p=0.13). The adjusted odds ratio (OR) for clinical cure with oral beta-lactams was 0.31 (95% CI 0.05 – 1.90, p=0.21); propensity score adjusted analysis showed a similar result. There was no statistically significant difference in secondary outcomes. Table 2

Table 2. Thirty-day outcomes for patients with E. coli bacteremic urinary tract infections

receiving oral fluoroquinolone or oral beta-lactam step down following initial empiric

intravenous beta-lactam therapy.

	Oral fluoroquinolone step down (n=130)	Oral beta- lactam step	p-value
		down (n=77)	
Primary Outcome			
Clinical cure	127 (98)	72 (94)	0.13
Secondary Outcomes			
30-day mortality	1 (1)	0 (0)	0.43
CDI	1 (1)	1 (1)	1
Length of hospitalization,	6 (3.25-9)	6 (4-10)	0.43
median, days (IQR)			

Data are number (percentage) of patients unless otherwise indicated.

Abbreviation: CDI, Clostridioides difficile infection.